In this publication, we show that our sublingual vaccine platform can be engineered to constitutively synthesize the attenuated cholera toxin-based adjuvant mmCT in situ leading to boosting of the mucosal immune response.
In this publication, we show that our sublingual vaccine platform can be engineered to constitutively synthesize the attenuated cholera toxin-based adjuvant mmCT in situ leading to boosting of the mucosal immune response.
Paula Watnick's Lab 